Join to view full profile
1500 Duarte RdDuarte, CA 91010
Phone+1 626-359-8111
Fax+1 626-408-3911
Dr. Leong is on Doximity
As a Doximity member, you’ll join more than three million U.S. healthcare professionals—including 85+% of physicians, and 2/3 of all NPs and PAs—in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Education & Training
City of Hope National Medical CenterFellowship, Hematology and Medical Oncology, 1983 - 1985
Los Angeles County-Harbor-UCLA Medical Center 1Fellowship, Hematology and Medical Oncology, 1982 - 1983- Los Angeles County-Harbor-UCLA Medical CenterResidency, Internal Medicine, 1979 - 1982
Stanford University School of MedicineClass of 1979
Certifications & Licensure
CA State Medical License 1981 - 2028
American Board of Internal Medicine Internal Medicine- American Board of Internal Medicine Hematology
- American Board of Internal Medicine Medical Oncology
Hospice and Palliative MedicinePalliative Medicine
Awards, Honors, & Recognition
- CMS Meaningful Use Stage 2 Certification Sunrise Ambulatory Care, Allscripts, 2013-2016
- CMS Meaningful Use Stage 1 Certification Allscripts FollowMyHealth, Allscripts, 2013-2016
- CMS Meaningful Use Stage 1 Certification Sunrise Ambulatory Care, Allscripts, 2013-2016
Clinical Trials
Publications & Presentations
PubMed
- 2 citationsOligometastatic Breast Cancer Patients Treated with High-Dose Chemotherapy and Targeted Radiation: Long-Term Follow-Up of a Phase II Trial.Colton Ladbury, Claire Hao, Christopher Ruel, Jason Liu, Scott Glaser
Cancers. 2022-10-13 - 24 citationsA phase I trial of intraperitoneal nab-paclitaxel in the treatment of advanced malignancies primarily confined to the peritoneal cavityMihaela C. Cristea, Paul Frankel, Timothy W. Synold, Saul E. Rivkin, Dean Lim
Cancer Chemotherapy and Pharmacology. 2019-01-08 - 16 citationsRandomized trial of oral cyclophosphamide versus oral cyclophosphamide with celecoxib for recurrent epithelial ovarian, fallopian tube, and primary peritoneal cancer.Rohan Gupta, Mihaela C. Cristea, Paul Frankel, Christopher Ruel, Chen Chen
Cancer Treatment and Research Communications. 2019-01-01
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
